Table 3 Summary of previously reported effects of enteral nutrition on the levels of VRCZ administered orally or via a tube
From: Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report
Williams11 | Martinez et al12 | Mohammedi et al13 | |
|---|---|---|---|
Study type | Case report | Case report | Prospective, observational, single-center study |
VRCZ dose | 11.6 mg/kg/day | 8 mg/kg/day | 6.2 ± 1.1 mg/kg/day |
VRCZ formulation, Administration route | Suspension, Per oral | Crushed VRCZ tablets, Jejunostomy tube | Crushed VRCZ tablets, Nasogastric tube |
Nutritional route | Nasojejunal tube | NR | Nasogastric tube |
Type of EN (composition) | ISOSOURCE® HN (29% caloric content of fat) | NR | NR |
EN method | Continuous | NR | Interrupted only for the duration of VRCZ administration |
Patients, Age | 1 post-transplantion, age 13 years | 1 with esophageal cancer, age 66 years | 6 with hematological malignancies (4 acute leukemia, 2 myeloma), 1 with solid tumor, and 1 with invasive pulmonary aspergillosis, age 63 ± 12 years |
Patients, Race | Hispanic | NR | NR |
The purpose of VRCZ therapy | Prophylactic therapy | Candida grabrata infection | 4 patients, voriconazole therapy was given for a microbiologically documented fungal infection. In total, five fungal pathogens were isolated (4 Aspergillus fumigatus and 1 Candida kefyr). |
Serum VRCZ levels (days after starting tube administration) | 1.07 mg/dL decreased to undetectable (On day8, 15)It was not mentioned that whether these were trough levels or not. | Ctrough: 1.7, 1.75, 1.4 mg/L Cpeak: 2.5, 2.55, 2.6 mg/L (On days 2, 8, 28) | Ctrough: 4.6 ± 2.8 mg/L Cpeak: 6.4 ± 4.3 mg/L(On days 3–44, mean 16 days) |
Assay method | NR | Solid-phase extraction followed by reversed liquid phase chromatography with UV detection. | Solid-phase extraction followed by reversed liquid phase chromatography with UV detection |